Literature DB >> 4044741

Detection and separation of mitoxantrone and its metabolites in plasma and urine by high-performance liquid chromatography.

G Ehninger, B Proksch, E Schiller.   

Abstract

A high-performance liquid chromatographic method using ion-pair chromatography on reversed-phase C18 material was developed. After sample clean-up on XAD columns, mitoxantrone at concentrations below 1 ng/ml in serum and 0.2 ng/ml in urine were measurable with a coefficient of variation of less than 9.3% at a wavelength of 658 nm. Four metabolites were separated in urine. The two major metabolites co-chromatographed with the synthesized mono- and dicarboxylic acid derivatives of mitoxantrone. The method allowed the measurement of mitoxantrone and its metabolites in serum up to more than one week and in urine up to four weeks after administration of the drug.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4044741     DOI: 10.1016/s0378-4347(00)84494-1

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

1.  Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.

Authors:  J Cummings; I Meikle; J S Macpherson; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 2.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

3.  Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells.

Authors:  H G Mergenthaler; P Brühl; G Ehninger; E Heidemann
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Are reduced quinones necessarily involved in the antitumour activity of quinone drugs?

Authors:  J Butler; B M Hoey
Journal:  Br J Cancer Suppl       Date:  1987-06

5.  Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.

Authors:  B Richard; M C Launay-Iliadis; A Iliadis; S Just-Landi; D Blaise; A M Stoppa; P Viens; M H Gaspard; D Maraninchi; J P Cano
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.